{"analyses":[{"ciLowerLimit":"0.697","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.903","estimateComment":"Analysis was performed on stratified data.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.0005","paramType":"Hazard Ratio (HR)","paramValue":"0.793","statisticalComment":"Analysis was performed on stratified data.","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.5","upperLimit":"6.2","value":"5.7"},{"groupId":"OG001","lowerLimit":"4.2","upperLimit":"5.4","value":"4.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"536"},{"groupId":"OG001","value":"536"}],"units":"Participants"}],"description":"PFS was defined as the time from the date of randomization until the date of objectively determined progressive disease (PD) \\[according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v). 1.1\\] or death due to any cause, whichever was first. PD is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). Participants who died without a reported prior progression were considered to have progressed on the day of their death. Participants who did not progress or were lost to follow-up were censored at the day of their last radiographic tumor assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"On Day 1 of each 14-day cycle, participants received ramucirumab followed by other study treatment in the following sequence: Irinotecan, Folinic Acid and 5-Fluorouracil. Treatment continued until disease progression, unacceptable toxicity, or other withdrawal criteria were met.\n\nRamucirumab: 8 mg/kg administered intravenously.\n\nIrinotecan: 180 mg/m\\^2 administered intravenously.\n\nFolinic Acid: 400 mg/m\\^2 administered intravenously.\n\n5-Fluorouracil: 400 mg/m\\^2 bolus immediately followed by 2400 mg/m\\^2 continuous infusion.","id":"OG000","title":"Ramucirumab + FOLFIRI"},{"description":"On Day 1 of each 14-day cycle, participants received placebo followed by other study treatment in the following sequence: Irinotecan, Folinic Acid and 5-Fluorouracil. Treatment continued until disease progression, unacceptable toxicity, or other withdrawal criteria were met.\n\nPlacebo: Administered intravenously.\n\nIrinotecan: 180 mg/m\\^2 administered intravenously.\n\nFolinic Acid: 400 mg/m\\^2 administered intravenously.\n\n5-Fluorouracil: 400 mg/m\\^2 bolus immediately followed by 2400 mg/m\\^2 continuous infusion.","id":"OG001","title":"Placebo + FOLFIRI"}],"paramType":"MEDIAN","populationDescription":"All randomized participants. Participants censored: Ramucirumab + FOLFIRI = 60; Placebo + FOLFIRI = 42.","reportingStatus":"POSTED","timeFrame":"Randomization to Measured PD or Date of Death from Any Cause Up to 38.01 Months","title":"Progression-free Survival (PFS) Time","type":"SECONDARY","unitOfMeasure":"months"}